<SEC-DOCUMENT>0001171843-17-000680.txt : 20170206
<SEC-HEADER>0001171843-17-000680.hdr.sgml : 20170206
<ACCEPTANCE-DATETIME>20170206080322
ACCESSION NUMBER:		0001171843-17-000680
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20170206
FILED AS OF DATE:		20170206
DATE AS OF CHANGE:		20170206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RedHill Biopharma Ltd.
		CENTRAL INDEX KEY:			0001553846
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35773
		FILM NUMBER:		17574084

	BUSINESS ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
		BUSINESS PHONE:		972-3-541-3131

	MAIL ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_020617.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><html lang="en-US"><head><title>EdgarFiling</title><meta content="text/html; charset=windows-1252"><meta name="GENERATOR" content="MSHTML 8.00.7601.18094"></head><body style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><div align="center"><div style="margin-top: 3pt; margin-bottom: 12pt;"><div style="font-size: 1pt; border-top: Black 2.5pt solid; border-bottom: Black 1.1pt solid; width: 100%;">&#160;</div></div><p style="font-size: 14pt;" align="center"><strong>UNITED STATES</strong><br><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br><strong>Washington, D.C. 20549</strong></p><p style="font-size: 14pt; text-transform: uppercase;" align="center"><strong>Form 6-K</strong></p><p><strong></strong></p><p><strong>Report of Foreign Private Issuer<br>Pursuant to Rule 13a-16 or 15d-16<br>of the Securities Exchange Act of 1934</strong></p><p>For the month of February 2017<br>Commission File No.:&#160;001-35773&#160;</p><p><strong>REDHILL BIOPHARMA LTD.</strong><br>(Translation of registrant's name into English)</p><p><strong>21 Ha'arba'a Street, Tel Aviv, 64739, Israel</strong><br>(Address of principal executive office)</p></div><p>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.<br>Form 20-F [&#160;X ] &#160;&#160;&#160;&#160;&#160;Form 40-F [&#160;&#160; ]</p><p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&#160;<samp style="text-decoration: underline;">&#160;</samp></p><p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&#160;<samp style="text-decoration: underline;">&#160;</samp></p><p><p>Attached hereto and incorporated by reference herein is a press release issued by the Registrant entitled: &#8220;<em>RedHill Biopharma to Present at the BIO CEO &amp; Investor Conference</em>&#8221;</p><p>This Form 6-K is incorporated by reference into the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286) and on October 29, 2015 (Registration No. 333-207654) and its Registration Statement on Form F-3 filed with the Securities and Exchange Commission on February 25, 2016 (Registration No. 333- 209702).</p></p><hr style="page-break-after: always;" noshade="noshade"><p style="text-align: center;"><strong>SIGNATURES</strong></p><p>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="font-family: Times New Roman; font-size: 10pt;" border="0" width="100%" cellspacing="0" cellpadding="0"><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%">REDHILL BIOPHARMA LTD.</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%">(Registrant)</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%"></td></tr><tr valign="top"><td width="47%">Date:&#160;February 6, 2017</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%">By: <u>/s/ Dror Ben-Asher</u></td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%">Dror Ben-Asher</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%">Chief Executive Officer</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%"></td></tr></table></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<html lang="en-US">
<head>
<title>EdgarFiling</title><meta content="text/html; charset=windows-1252"><meta name="GENERATOR" content="MSHTML 8.00.7601.18094"></head>
<body bgcolor="#ffffff">

<p style="text-align: right;"><strong>EXHIBIT 99.1</strong></p>

<p style="text-align: center;"><strong>RedHill Biopharma to Present at the BIO CEO &amp; Investor Conference</strong></p>

<p style="text-align: center;">

<p>

<p align="justify">TEL-AVIV, Israel, Feb.  06, 2017  (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (&#8220;RedHill&#8221; or the &#8220;Company&#8221;), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that Mr. Dror Ben-Asher, RedHill&#8217;s Chief Executive Officer, will present a corporate overview at the BIO CEO &amp; Investor Conference, on <strong>Monday, February 13, 2017, at 3:30 pm EST</strong>,&#160;at The Waldorf Astoria Hotel, New York City.<br></p>

<p align="justify"><strong>A live audio of the presentation will be available on the Company's website at: http://ir.redhillbio.com/events.cfm.</strong> A copy of the presentation is available on the Company's website and a replay of the webcast will be available on the Company's website for a period of 30 days.</p>

<p align="justify"><strong>About RedHill Biopharma Ltd.:&#160;&#160;&#160;&#160;&#160; </strong><br> RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) is a specialty biopharmaceutical company headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. RedHill has a U.S. co-promotion agreement with Concordia for <strong>Donnatal<sup>&#174;</sup></strong>, a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis. RedHill&#8217;s clinical-stage pipeline includes: (i) <strong>RHB-105</strong> <strong>-</strong> an oral combination therapy for the treatment of <em>Helicobacter pylori</em> infection with successful results from a first Phase III study; (ii) <strong>RHB-104</strong> <strong>-</strong> an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis and a QIDP status for NTM; (iii) <strong>BEKINDA<sup>&#174;</sup></strong><strong> (RHB-102)</strong> <strong>-</strong> a once-daily oral pill formulation of ondansetron with an ongoing Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; (iv) <strong>RHB-106</strong> <strong>-</strong> an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v) <strong>YELIVA<sup>&#174;</sup> (ABC294640)</strong> <strong>-</strong> a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications; (vi) <strong>MESUPRON - </strong>a Phase II-stage first-in-class, orally-administered uPA inhibitor, targeting gastrointestinal and other solid tumors and (vii)<strong> RIZAPORT<sup>&#174;</sup> (RHB-103) -</strong> an oral thin film formulation of rizatriptan for acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received in Germany in October 2015. More information about the Company is available at: www.redhillbio.com.</p>

<p align="justify"><em>This press release contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;estimates,&#8221; &#8220;aims,&#8221; &#8220;believes,&#8221; &#8220;hopes,&#8221; &#8220;potential&#8221; or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company&#8217;s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company&#8217;s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts; (ii) the Company&#8217;s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; (iii) the extent and number of additional studies that the Company may be required to conduct and the Company&#8217;s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company&#8217;s therapeutic candidates; (v) the Company&#8217;s ability to establish and maintain corporate collaborations; (vi) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (vii) the interpretation of the properties and characteristics of the Company&#8217;s therapeutic candidates and of the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (viii) the implementation of the Company&#8217;s business model, strategic plans for its business and therapeutic candidates; (ix) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (x) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xi) estimates of the Company&#8217;s expenses, future revenues capital requirements and the Company&#8217;s needs for additional financing; (xii) competitive companies and technologies within the Company&#8217;s industry; and (xiii) the impact of the political and security situation in Israel on the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC </em><em>on February 25, 2016. All forward-looking statements included in this Press Release are made only as of the date of this Press Release. We assume no obligation to update any written or oral forward-looking statement unless required by law.</em></p></p>

<p>Company contact:<br>Adi Frish<br>Senior VP Business Development &amp; Licensing<br>RedHill
Biopharma<br>+972-54-6543-112<br>adi@redhillbio.com<br><br>IR contact (U.S.):<br>Marcy Nanus<br>Senior Vice President<br>The
Trout Group<br>+1-646-378-2927<br>Mnanus@troutgroup.com</p>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
